Protagenic Therapeutics Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
PTIX
- Investments
-
1
- Share Price
-
$0.55
- (As of Tuesday Closing)
Protagenic Therapeutics General Information
Description
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Contact Information
Website
www.protagenic.comCorporate Office
- 149 Fifth Avenue
- Suite 500
- New York, NY 10010
- United States
Corporate Office
- 149 Fifth Avenue
- Suite 500
- New York, NY 10010
- United States
Protagenic Therapeutics Stock Performance
As of 03-Dec-2024, Protagenic Therapeutics’s stock price is $0.55. Its current market cap is $3.74M with 6.79M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.55 | $0.47 | $0.45 - $1.87 | $3.74M | 6.79M | 382K | -$1.27 |
Protagenic Therapeutics Financials Summary
As of 30-Sep-2024, Protagenic Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,878 | (462) | (920) | 13,191 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (5,659) | (5,129) | (3,604) | (4,059) |
| Net Income | (5,648) | (5,000) | (3,556) | (4,523) |
| Total Assets | 1,508 | 4,323 | 8,037 | 11,060 |
| Total Debt | 0 | 0 | 344 | 318 |
Protagenic Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Protagenic Therapeutics Comparisons
Industry
Financing
Details
Protagenic Therapeutics Competitors (15)
One of Protagenic Therapeutics’s 15 competitors is Voyager Therapeutics, a Corporation company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Voyager Therapeutics | Corporation | Lexington, MA | ||||
| Parion Sciences | Venture Capital-Backed | Durham, NC | ||||
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| Tricida | Formerly VC-backed | Sacramento, CA | ||||
| Omeros | Formerly VC-backed | Seattle, WA |
Protagenic Therapeutics Patents
Protagenic Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220062380-A1 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction | Pending | 13-Mar-2018 | ||
| CA-3093841-A1 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction | Pending | 13-Mar-2018 | ||
| EP-3765056-A1 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction | Active | 13-Mar-2018 | ||
| EP-3765056-C0 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction | Active | 13-Mar-2018 | ||
| EP-3765056-B1 | Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction | Active | 13-Mar-2018 | A61K38/17 |
Protagenic Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Protagenic Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Protagenic Therapeutics Acquisitions (1)
Protagenic Therapeutics’s most recent deal was a Merger/Acquisition with Atrinsic. The deal was made on 12-Feb-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Atrinsic | 12-Feb-2016 | Merger/Acquisition | Media and Information Services (B2B) |
Protagenic Therapeutics FAQs
-
When was Protagenic Therapeutics founded?
Protagenic Therapeutics was founded in 1994.
-
Where is Protagenic Therapeutics headquartered?
Protagenic Therapeutics is headquartered in New York, NY.
-
What is the size of Protagenic Therapeutics?
Protagenic Therapeutics has 2 total employees.
-
What industry is Protagenic Therapeutics in?
Protagenic Therapeutics’s primary industry is Biotechnology.
-
Is Protagenic Therapeutics a private or public company?
Protagenic Therapeutics is a Public company.
-
What is Protagenic Therapeutics’s stock symbol?
The ticker symbol for Protagenic Therapeutics is PTIX.
-
What is the current stock price of Protagenic Therapeutics?
As of 03-Dec-2024 the stock price of Protagenic Therapeutics is $0.55.
-
What is the current market cap of Protagenic Therapeutics?
The current market capitalization of Protagenic Therapeutics is $3.74M.
-
Who are Protagenic Therapeutics’s competitors?
Voyager Therapeutics, Parion Sciences, Vedanta Biosciences, Tricida, and Omeros are some of the 15 competitors of Protagenic Therapeutics.
-
What is Protagenic Therapeutics’s annual earnings per share (EPS)?
Protagenic Therapeutics’s EPS for 12 months was -$1.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
